NEW YORK (GenomeWeb News) — Lipomics today said it will provide its lipid metabolite services to Isis Pharmaceuticals.
 
Under the terms of the agreement, Lipomics will support Isis in its pre-clinical and clinical trials of lipid compounds that may be used to treat metabolic diseases.
 
Lipomics said it will hold exclusive rights to develop diagnostics that result from the research, while Isis will retain rights to therapeutics.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.

Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.

In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.